POS0115 SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) AND CARDIOVASCULAR RISK IN SYSTEMIC LUPUS ERYTHEMATOSUS: A LONGITUDINAL COHORT STUDY
| العنوان: | POS0115 SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) AND CARDIOVASCULAR RISK IN SYSTEMIC LUPUS ERYTHEMATOSUS: A LONGITUDINAL COHORT STUDY |
|---|---|
| المؤلفون: | C. C. Mok, K. L. Chan, L. Y. Ho, S. M. Tse, C. H. To |
| المصدر: | Annals of the Rheumatic Diseases. 81:282.1-283 |
| بيانات النشر: | BMJ, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Rheumatology, Immunology, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology |
| الوصف: | ObjectivesTo study the effect of serum PCSK9 on major cardiovascular adverse events (MACEs) in Chinese patients with systemic lupus erythematosus (SLE).MethodsConsecutive patients who fulfilled ≥4 1997 ACR criteria for SLE and consented for a biomarker study between 2009 and 2012 were included. Stored serum samples from these patients were assayed for the levels of PCSK9 using a commercial ELISA kit (OKBB00903, Lot# 1344, Aviva Systems Biology, San Diego, US). New MACEs (acute coronary syndrome, ischemic stroke, peripheral vascular disease) documented by imaging and angiographic studies over time was evaluated. Patients were stratified into high/low PCSK9 groups according to the best cut-off level by ROC analysis for the prediction of these events. The cumulative incidence of new MACEs and mortality over time was studied by Kaplan-Meier’s analysis and compared between the high and low PCSK9 subgroups. Cox regression was performed to study the effect of the PCSK9 subgroups on new MACEs and mortality, adjusted for other confounding factors.Results539 SLE patients were studied (93% women, age 41.9±14.0 years; disease duration 106±90.4 months at entry). The mean PCSK level at baseline was 265±158ng/ml and a cut-off of 243.25ng/ml best predicted a new vascular event by the maximum Youden’s index (ROC analysis: AUC 0.63[0.51-0.74]; sensitivity 69%; specificity 61%). 220 SLE patients had baseline PCSK9 level of ≥243.25ng/ml (high PCSK9) and 319 patients had level below 243.25ng/ml (low PCSK9). Patients with high PCSK9 (n=220) had more active SLE than those with low PCSK9 (n=319) (pConclusionHigh circulating levels of PCSK9 increase the risk of MACEs and vascular mortality in patients with SLE.Disclosure of InterestsNone declared |
| تدمد: | 1468-2060 0003-4967 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::711139e3e02adcf1a13a029af69967c6 https://doi.org/10.1136/annrheumdis-2022-eular.1441 |
| رقم الأكسشن: | edsair.doi...........711139e3e02adcf1a13a029af69967c6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14682060 00034967 |
|---|